tiprankstipranks
Rezolute (DE:6HV1)
BERLIN:6HV1

Rezolute Stock Price & Analysis

0 Followers

6HV1 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€2.06 - €8.56
Previous Close€2.26
Volume0.00
Average Volume (3M)N/A
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)€6.40M
Total Debt (Recent Filing)€187.00K
P/E RatioN/A
Beta-0.85
Next EarningsNov 11, 2022
EPS Estimate-€0.39
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)N/A
Shares OutstandingN/A
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
P/B RatioN/A
P/S RatioN/A
P/CF RatioN/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside554.69% Upside
Rating ConsensusStrong Buy
AlphaN/A
Number of Analyst Covering4


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

6HV1 FAQ

What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was €2.06 and its highest was €8.56 in the past 12 months.
    What is Rezolute’s market cap?
    Currently, no data Available
    When is Rezolute’s upcoming earnings report date?
    Rezolute’s upcoming earnings report date is Nov 11, 2022 which is in 45 days.
      How were Rezolute’s earnings last quarter?
      Rezolute released its earnings results on Sep 15, 2022. The company reported -€0.383 earnings per share for the quarter, beating the consensus estimate of -€0.421 by €0.037.
        Is Rezolute overvalued?
        According to Wall Street analysts Rezolute’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Rezolute pay dividends?
          Rezolute does not currently pay dividends.
          What is Rezolute’s EPS estimate?
          Rezolute’s EPS estimate is -€0.39.
            How many shares outstanding does Rezolute have?
            Currently, no data Available
            What happened to Rezolute’s price movement after its last earnings report?
            Rezolute reported an EPS of -€0.383 in its last earnings report, beating expectations of -€0.421. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Rezolute?
              Currently, no hedge funds are holding shares in DE:6HV1

              ---

              Rezolute Stock Analysis

              Smart ScoreNeutral
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10
              4

              Analyst Consensus

              Strong Buy
              Average Price Target: €14.80

              Blogger Sentiment

              Bullish
              DE:6HV1 Sentiment 100% Sector Average 70%

              Insider Transactions

              N/A
              Currently Not Enough Data Available

              News Sentiment

              Neutral
              Bullish 100% Bearish 0%

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -65.96%
              12-Months-Change

              Fundamentals

              Return on Equity
              -46.77%
              Trailing 12-Months
              Asset Growth
              257.72%
              Trailing 12-Months
              The Rezolute Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
              Learn more about TipRanks Smart Score

              Company Description

              Rezolute

              Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              AbbVie
              Amgen
              Gilead Sciences
              Moderna
              Vertex Pharmaceuticals

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis